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Abstract
Background: Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that typically causes asymptomatic 
infections in healthy individuals but may lead to serious complications in newborns and immunodeficient individuals. 
The emergence of drug-resistant strains of HCMV has posed a need for the development of new drugs and treatment 
strategies. Antisense molecules are promising gene-targeting agents for specific regulation of gene expression. 
External guide sequences (EGSs) are oligonucleotides that consist of a sequence complementary to a target mRNA and 
recruit intracellular RNase P for specific degradation of the target RNA. The UL49-deletion BAC of HCMV was 
significantly defective in growth in human foreskin fibroblasts. Therefore, UL49 gene may serve as a potential target for 
novel drug development to combat HCMV infection. In this study, DNA-based EGS molecules were synthesized to 
target the UL49 mRNA of human cytomegalovirus (HCMV).
Results: By cleavage activity assessing in vitro, the EGS aimed to the cleavage site 324 nt downstream from the 
translational initiation codon of UL49 mRNA (i.e. EGS324) was confirmed be efficient to direct human RNase P to cleave 
the target mRNA sequence. When EGS324 was exogenously administered into HCMV-infected human foreskin 
fibroblasts (HFFs), a significant reduction of ~76% in the mRNA and ~80% in the protein expression of UL49 gene, 
comparing with the cells transfected with control EGSs. Furthermore, a reduction of about 330-fold in HCMV growth 
were observed in HCMV-infected HFFs treated with the EGS.
Conclusions: These results indicated that UL49 gene was essential for replication of HCMV. Moreover, our study 
provides evidence that exogenous administration of a DNA-based EGS can be used as a potential therapeutic 
approach for inhibiting gene expression and replication of a human virus.
Background
Human cytomegalovirus is a ubiquitous herpesvirus that
typically causes asymptomatic infections in healthy indi-
viduals but may lead to serious complications in new-
borns and immunodeficient individuals. For example,
this virus accounts for one of the most common opportu-
nistic infections in AIDS patients (i.e., CMV retinitis).
Moreover, HCMV infection is the leading viral cause of
birth defects in newborns and a major cause of morbidity
and mortality in bone marrow and solid organ transplant
recipients [1]. The emergence of drug-resistant strains of
HCMV has posed a need for the development of new
drugs and treatment strategies [2].
Antisense molecules are promising gene-targeting
agents for specific regulation of gene expression [3]. Con-
ventional antisense oligonucleotides have been used as
anti-HCMV agents to inhibit the expression of HCMV-
essential genes and abolished viral replication [4,5].
External guide sequences (EGSs) are antisense oligonu-
cleotides that can be used in conjunction with ribonu-
clease P (RNase P) or the catalytic RNA subunit of RNase
P from Escherichia coli (M1 RNA) to diminish gene
expression [6-9]. RNase P is one of the most abundant
and active enzymes in cells and is responsible for 5' ter-
mini maturation of tRNAs [10]. This enzyme catalyzes a
hydrolysis reaction to remove the 5' leader sequence of
tRNA precursors (ptRNA) by recognizing the common
* Correspondence: tzth@jnu.edu.cn
1 National Engineering Research Center of Genetic Medicine, Jinan University, 
Guangzhou, 510632, China
Full list of author information is available at the end of the articleZhang et al. Virology Journal 2010, 7:100
http://www.virologyj.com/content/7/1/100
Page 2 of 8
structure shared among all tRNAs (Fig. 1A). The EGS-
based technology is unique in inducing endogenous
RNase P to cleave a target mRNA when the EGS hybrid-
izes to the mRNA to form a structure resembling a
ptRNA substrate (Fig. 1B). This approach is highly spe-
cific and does not generate nonspecific "irrelevant cleav-
a g e "  t h a t  i s  o b s e r v e d  i n  R N a s e  H - m e d i a t e d  c l e a v a g e
induced by conventional antisense phosphothioate mole-
cules [11]. Thus, EGSs represent a new class of agents
that may lead to highly effective and specific inhibition of
gene expression.
RNA-based EGSs have been expressed endogenously as
transgenes in both bacteria and mammalian cells [12],
and were effective in inhibiting the gene expression of
herpes simplex and influenza virus and in abolishing the
replication of influenza virus in human cells [13,14]. In
vitro studies have also shown that DNA-based EGSs, as
w e l l  a s  E G S  m o l e c u l e s  w i t h  m o d i f i e d  n u c l e o t i d e s,  c a n
direct M1 RNA or human RNase P to cleave a mRNA
sequence, although their targeting efficiencies are lower
than those of unmodified RNA-based EGSs [15]. How-
ever, little is known about whether DNA-based EGSs are
functionally active in cultured cells. Also, whether DNA-
based EGSs can be exogenously administered into human
c e l l s  t o  i n h i b i t  g e n e  e x p r e s s i o n  a n d  g r o w t h  o f  h u m a n
viruses is yet to be determined.
The UL49-deletion BAC of HCMV was significantly
defective in growth in human foreskin fibroblasts [16].
Furthermore, the expression of HCMV UL49 protein has
been shown in our mock infected human foreskin fibro-
blasts (unpublished data, doctoral dissertation). There-
fore, UL49 gene may serve as a potential target for novel
drug development to combat HCMV infection. In this
study, we provide direct evidence that exogenous admin-
istration of chemically synthesized DNA-based EGS is
highly effective in inhibiting HCMV gene expression and
growth in human cell culture and, furthermore, demon-
strate the feasibility of using DNA-based EGSs for the
studies and treatment of infections caused by human
viruses including HCMV.
Materials and methods
Construction of the RNA substrate and EGSs
The DNA sequence that encodes HCMV UL49 gene was
constructed by PCR using AD169 genomic DNA as a
template and oligonucleotides 49F: 5'-AGTTGGATCCA-
TGGCCAGTCGTCGTCTC-3' and 49R: 5'-
ATCTAAGCTTGTAGACATGGGGCAGGCCGT-3' as
5' and 3' primers, respectively. The PCR fragments were
digested with BamH I and Hind III, and then inserted
into vector pGEM3z (Invitrogen) to form a recombinant
plasmid, UL49-pGEM3z. The RNA substrates were syn-
thesized by bacteriophage T7 RNA polymerase using the
Hind III-linearized UL49-pGEM3z plasmid as transcrip-
tional templates and labeled with 32P-UTP. The restric-
tion endonucleases, LA Taq polymerase, T4 DNA ligase
and T7 RNA polymerase were purchased from Takara
(Dalian, China). All oligonucleotides used as PCR prim-
ers were purchased from Invitrogen (Guangzhou, China).
EGS oligonucleotides used in this report including
EGS324(5' CGACACACTTGGGGTTTCCCCACG-
CAGGT TCGAATCCTGCGCCATTCCCA3'), EGS15
39(5'GTCGCG GTTGGGGTTTCCCCAC GCAGGT
TCGAATCCTGCCTCGCCCCCA3'), C-EGS324(5' CGA
CACACTTGGGG TTTCCCCACGCAGGAAGGA ATC
CTGCG CCA TTCCCA3'), C-EGS1539(5'GTCG CGGT-
TGGGGTTTCCCCACGCAGGAAGGAATCCTGCCT
CGCCCCCA3'), and TK-EGS(5'TACGTCGGTGC GG
TCTCCGCGCGCAGGTTCAAATCCTGCCGCAGAC
ACCA3') were chemically synthesized directly by using a
DNA synthesizer.
Purification of human RNase P
RNase P was purified from HeLa cells according to the
method as described [17] with the following modifica-
tions. The DEAE-Sepharose Fast-flow column was equili-
brated and washed with buffer A containing 10 mM Tris-
Figure 1 Schematic representation of substrates for RNase P. (A) A natural substrate (ptRNA). (B) A hybridized complex of a target RNA (e.g., mR-
NA) and an EGS that resembles the structure of a tRNA. (C-F) Complexes between UL49 mRNA sequence and EGS324, C-EGS324, EGS1539, and C-
EGS1539 respectively. The sequence of these EGSs equivalent to the tRNA sequence was derived from tRNASer and resembles the T-stem and loop, 
and variable region of the tRNA molecule.Zhang et al. Virology Journal 2010, 7:100
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HCl, pH 7.5, 2.5 mM MgCl2, 5 mM KCl, 2 mM DTT, and
1 mM Pefabloc (proteinase inhibitor). The enzyme was
eluted with a linear gradient of 100~500 mM KCl in the
same buffer. The active fractions were pooled and con-
centrated to a final volume of approximately 5 ml. The
active fractions were pooled and dialyzed against a buffer
containing 10 mM Tris-HCl, pH 7.5, 2.5 mM MgCl2, 5
mM KCl, 2 mM DTT, 1 mM Pefabloc and 50% glycerol.
The samples were then stored at -80°C before use. The
specific activity of the RNase P was determined as the
cleavage of 0.02 pmol yeast tRNAser precursor per min
per μl.
In vitro cleavage studies
The EGSs (50 nM) and 32P-labeled UL49 mRNA (50 nM)
were incubated with human RNase P (5 units). The cleav-
age reactions were carried out at 37°C for 30 min in buffer
A (50 mM Tris-HCl, pH7.5, 100 mM NH4Cl, 10 mM
MgCl2). To disrupt aggregates, which might form during
storage, EGS and substrate together were heated to 90°C
for 1 min and then cooled to room temperature before
the addition of other components. Substrate and cleavage
products were separated under denaturing conditions on
a 15% acrylamide gel containing 8 M urea. The amount of
radioactivity per band was quantified using a Typhoon
9200  phosphorimager. The procedures to measure the
equilibrium dissociation constants (Kd) of the EGS-UL49
mRNA complexes were carried out as described [18]. In
brief, various concentrations of EGSs were preincubated
in buffer B (50 mM Tris, pH 7.5, 100 mM NH4Cl, 20 mM
MgCl2, 3% glycerol, 0.1% xylene cyanol, 0.1% bromphenol
blue) at 37°C for 10 min before mixing with an equal vol-
ume of different concentrations of 32P-labeled substrate
RNA preheated under identical conditions. The samples
were incubated for 15 min to allow binding, loaded on a
5% polyacrylamide gel, and run at 10 watts. The electro-
phoresis running buffer contained 100 mM Tris-Hepes,
pH 7.5, and 10 mM MgCl2. Each band was quantitated
with a Typhoon 9200 phosphorimager. The value of Kd
was then extrapolated from a graph plotting percentage
of product bound versus EGS concentration. The values
were the average of three experiments.
EGS internalization and viral infection
Lipofectamine 2000 reagent (GIBCO) was diluted in 100
μl of Opti-MEM medium with the EGS to give a final
concentration of 10 ug/ml lipid-100 nM EGS. The trans-
fection experiments were carried out by using 100 nM
EGS. The EGS-lipid mixtures were prepared according to
the manufacturer's recommendation (GIBCO) and incu-
bated with cells for 7 hrs. HCMV (strain AD169) was
propagated in human foreskin fibroblasts in DMEM sup-
plemented with 10% FBS (GIBCO). Cells (1 × 106) were
treated with liposome complexes in the absence and pres-
ence of EGS, followed by HCMV infection or mock infec-
tion at a MOI of 1 in an inoculum of 1.5 ml DMEM
supplemented with 1% fetal calf serum (FCS). Total cellu-
lar RNAs and proteins were isolated from cells as
described 72 hrs postinfection [19].
Fluorescence Quantitative RT-PCR
Fluorescence Quantitative RT-PCR (FQ-RT-PCR) was
performed using standard protocols on an Applied Bio-
system's 7300 Sequence Detection System. Briefly, total
RNAs were extracted using Trizol, then 5 ml of a 1/100
dilution of cDNA in water was added into 12.5 ml of the 2
× SYBR green PCR master mix (Takara), with 800 nM of
each primer in a total volume of 25 ml. All reactions were
run in triplicate using Applied Biosystem's 7300 Sequence
Detection System. UL49 gene sense primer: 5'-CGTTCT-
TGCGTCCTTCATCT-3'; anti-sense primer: 5'-
CACAAAGTAGGGCTTGGTCAT-3'. As internal stan-
dard, a fragment of human endogenous β actin was
amplified simultaneously in each PCR. β actin sense
primer: 5'-TCGTCCACCGCAAATGCTTCTAG-3', anti-
sense primer: 5'-ACTGCTGTCACCTTCACCGTTCC-
3'. Quantitative RT-PCR conditions: 95°C for 10 s, 1 cycle,
followed by 95°C for 5 s, 60°C for 20 s, 40 cycles for ampli-
fying UL49 and β actin.
Western blotting
For Western analyses, the denatured, solubilized poly-
peptides were separated on 12% (vol/vol) SDS polyacryl-
a m i d e  g e l s  c r o s s - l i n k e d  w i t h  N ,  N " -
methylenebisacylamide, and then transferred onto PVDF
membranes (Amersham, Freiburg, Germany). The mem-
branes were incubated in the primary antibody solution
(including antibody against human β actin, ul49, IE1/IE2,
pp28, or gB), then were incubated in a goat anti-mouse
HRP-conjugated antibody solution. After washing with
PBS containing 0.05% Tween 20, the membranes were
subsequently stained with a chemiluminescent substrate
with the aid of a Western chemiluminescent substrate kit
(Pierce, Rockford) and quantitated with a Typhoon 9200
phosphorimager [20]. The polyclonal antibodies against
HCMV UL49 protein were kindly provided by Doctor
Feng Zhu (BOAOSEN, Beijing). The monoclonal anti-
bodies, which react with HCMV proteins gB, pp28 and
IE1/IE2, respectively, were purchased from SANTA
CRUS. The monoclonal antibodies against human β actin
was purchased from SIGMA.
Assay of viral growth in EGS-treated cells
To determine the level of the inhibition of viral growth, 5
× 105 human foreskin fibroblasts were first incubated
with liposome complexes in the absence and presence of
EGSs, and then mock-infected or infected with HCMVZhang et al. Virology Journal 2010, 7:100
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AD169 at a MOI of 1. The cells and medium were har-
vested at 1, 2, 3, 4, 5, 6, and 7 days postinfection. The viral
stocks were prepared by adding an equal volume of 10%
skim milk, followed by sonication. The titers of the viral
s t o c k s  w e r e  d e t e r m i n e d  b y  i n f e c t i n g  2  ×  1 0 5 foreskin
fibroblasts in 6-well plates and counting the number of
plaques 7~10 days postinfection. The values obtained
were the average from triplicate experiments.
Results
Design of EGSs
To achieve optimal cleavage, it is critical to choose the
target regions of the UL49 mRNA. According to general
principles of designing EGSs [21], two positions, 324 nt
and 1539nt downstream from the translational initiation
codon, were chosen as the cleavage sites for EGSs. The
flanking sequence of these cleavage sites exhibited several
s e q u e n c e  f e a t u r e s  t h a t  n e e d  t o  b e  p r e s e n t  i n  o r d e r  t o
interact with an EGS and RNase P to achieve efficient
cleavage. These features include that ? the nucleotides 3'
and 5' adjacent to the site of cleavage are a guanosine and
a pyrimidine, respectively, and ? a U is 8 nt downstream
from this cleavage site. The interactions of these
sequence elements with the EGS facilitate the formation
of the mRNA-EGS complex into a ptRNA-like structure
while those with RNase P are critical for recognition and
cleavage by the enzyme [22]. On the basis of the target
sites, two EGSs (EGS324 and EGS1539) were constructed
respectively, which resemble a part of the tRNASer struc-
ture, containing a T-loop, a stem, and a variable region
but not the anticodon region (Fig. 1C and 1E). The anti-
codon domain has been shown to be dispensable for EGS
activity. Binding of EGSs to the target mRNA results in a
helix structure of 7 bp that is equivalent to the D stem of a
tRNA, which usually has 4 bp. Our choice of a D stem-
equivalent structure of 7 bp instead of 4 bp is to increase
the targeting sequence specificity of the EGS (Fig. 1C and
1E). The two control (C-EGS324 and C-EGS1539) were
derived respectively from EGS324 and EGS1539 by intro-
ducing base substitution mutations in three positions of
the T-loop (Fig. 1D and 1F). The nucleotides in these
three positions are highly conserved among tRNA mole-
cules and are important for the recognition of tRNA mol-
ecules by RNase P [23].
In vitro studies of targeting activities of the EGSs
T h e  E G S s  w e r e  s u b s e q u e n t l y  i n c u b a t e d  w i t h  h u m a n
RNase P and substrate RNA, containing the targeted
UL49 mRNA sequence of 1713 nt. In the absence of any
E G S ,  n o  c l e a v a g e  o f  t h e  U L 4 9  m R N A  s e q u e n c e  w a s
observed (Fig. 2, lane 1). Efficient cleavage of this sub-
strate by RNase P was observed in the presence of
EGS324 (Fig. 2, lane 2). In contrast, cleavage of the same
substrate by RNase P was barely detected in the presence
of C-EGS324 (Fig. 2, lane 3). It is possible that the differ-
ential cleavage efficiencies observed with EGS324 and C-
EGS324 were due to their different binding affinities to
the UL49 mRNA sequence. To investigate whether this
was the case, the binding between the EGSs and substrate
UL49 was studied using a gel-shift assay. In this assay, the
EGSs were incubated with the substrate to allow for bind-
ing, and the EGS-UL49 mRNA complexes were separated
in polyacrylamide gels under non-denaturing conditions.
Similar amounts of complexes formed between these two
EGSs and the UL49 mRNA sequence were observed
when the same amount of EGSs was used (Fig. 3, lane1 &
lane 2). Further detailed assays under different concentra-
tions of the EGS324 and UL49 mRNA indicated that the
binding affinity of C-EGS324 to UL49 mRNA (Kd = 0.83 ±
0.12 μM) is similar to that of EGS324 (Kd = 0.82 ± 0.10
μM). Meanwhile, a very little amount of cleavage prod-
ucts was observed in the presence of C-EGS324 even
under high concentrations of the EGS and RNase P and a
prolonged incubation period (data not shown). These
observations suggest that the mutations in C-EGS324 do
not significantly affect the binding affinity of the EGS to
the mRNA sequence but abolish its targeting activity to
induce RNase P cleavage, possibly by disrupting the rec-
ognition of EGS-UL49 mRNA complex by RNase P. Thus,
C-EGS324 may be used as a control for the antisense
effect in our experiments in cultured cells (see below).
Nevertheless, both EGS1539 and C-EGS1539 showed no
activity in guiding RNase P to cleave the target RNA (Fig.
2, lane 4 & lane 5). An additional EGS, TK-EGS, which
was targeting the HSV-1 TK mRNA, was also con-
structed. This EGS was used to determine whether an
EGS with an incorrect targeting sequence can direct
human RNase P to cleave UL49 mRNA. No cleavage of
UL49 mRNA by RNase P was observed in vitro in the
presence of TK-EGS (Fig. 2, lane 6).
Inhibition of HCMV UL49 expression in EGS-treated cells
The chemically synthesized EGS molecules were com-
plexed with Lipofectamine 2000 liposomes and delivered
into human foreskin fibroblasts. Treatment of cells with
the EGS-liposome complexes by using our transfection
protocol consistently yielded a transfection efficiency of
about 90% (data not shown). To investigate whether the
internalized EGSs inhibit viral UL49 expression, the cells
were treated with EGSs and then infected with HCMV at
a moi of 1. The levels of viral UL49 mRNA were deter-
mined by quantitative RT-PCR analyses (Fig. 4). A reduc-
tion of 75.57 ± 3% in the level of UL49 mRNA expression
was observed in cells treated with EGS324, whereas a
reduction of less than 10% was observed in the cells
treated with C-EGS324. No reduction in the expressionZhang et al. Virology Journal 2010, 7:100
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l e v e l  o f  U L 4 9  m R N A  w a s  o b s e r v e d  i n  c e l l s  t h a t  w e r e
treated with liposome complexes in the absence of EGSs
or in the presence of TK-EGS. These results suggest that
the significant reduction of UL49 mRNA expression in
the EGS324-treated cells was due to targeted cleavage by
RNase P. The low level of inhibition observed in the C-
EGS324 treated cells was presumably due to the antisense
effects of the EGS.
To determine whether the inhibition of UL49 expres-
sion directed by EGS324 is dose-depended, the EGS324
were transfected into HFFs at different concentrations
(2.5, 5, 10, 20, 40, 80, and 160 nM), followed by infection
with HCMV at a moi of 1. At 72 hrs postinfection, total
RNAs were extracted using Trizol reagent, and then
quantitative RT-PCR were performed. The quantitative
RT-PCR showed that when the concentration of EGS324
was 2.5 nM, the inhibition efficiency was 15%; and then 5
nM was 22%, 10 nM was 31%, 20 nM was 43%, 40 nM was
51%, 80 nM was 75%, and 160 nM was 75.6% (Fig. 5). The
results showed that the inhibition efficiency of EGS324
was dose-dependent.
The expression level of UL49 protein was also deter-
mined by Western analyses (Fig. 6). A reduction of 80% ±
3% in the expression level of UL49 protein was observed
in cells treated with EGS324, whereas a reduction of less
than 10% was found in the C-EGS324 treated cells.
Inhibition of UL49 expression is not expected to affect the 
expression of other viral genes
It is possible that the observed reduction of UL49 expres-
sion in the EGS324-transfected cells is not necessarily
due to specific EGS-directed RNase P cleavage of the tar-
get mRNA, but is due to other effects of the EGS on viral
lytic replication, such as blocking the expression of viral
immediate-early genes. To exclude these possibilities and
further determine the antiviral mechanism of the EGS-
directed cleavage, we examined the expression of other
viral genes in the EGS324-treated cells. Relative RT-PCR
analyses were carried out to determine the mRNA levels
Figure 2 Cleavage of the 32 P-labeled substrate by human RNase 
P in the presence of different EGSs. No EGS was added to the reac-
tion mixture in lane 1. Cleavage reactions were carried out in the pres-
ence of EGS324 (lane 2), C-EGS324 (lane 3), EGS1539 (lane 4), C-
EGS1539 (lane 5) or TK-EGS (lane 6).
Figure 3 Binding of UL49 mRNA substrate by EGS324 and C-
EGS324. Substrate (10 nM) was either in the presence of 10 nM of 
EGS324 (lane 1), C-EGS324 (lane 2), or TK-EGS (lane 3) to allow binding 
and then loaded on a 5% polyacrylamide gel.Zhang et al. Virology Journal 2010, 7:100
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of an immediate-early gene (IE) and an early-late gene
(UL44). Moreover, Western analyses were performed to
determine the levels of viral protein IE2, a viral immedi-
ate-early (α) protein, gB, a viral early (β) protein, and
pp28, a viral late (γ) protein. No significant differences in
the expression levels of these genes were observed in cells
that were treated with liposome complexes in the absence
of EGS or in the presence of TK-EGS, EGS324, or C-
EGS324 (Table 1). These results suggest that EGS324 spe-
cifically inhibits the expression of UL49 and does not
affect overall viral gene expression.
Inhibition of HCMV growth in the EGS-treated cells
The impact of UL49 inhibition by EGS on viral growth
was further investigated. Cells were treated with lipo-
some complexes in the absence and presence of EGSs and
then infected by HCMV at an moi of 1. Virus stocks were
prepared from the infected cultures at 1-day intervals
through 7 days postinfection. The count of plaque-form-
ing units (PFU) was determined by measurement of the
viral titer on cells. After 4 days postinfection, a reduction
of about 330-fold in viral yield was observed in the
EGS324-treated cells, whereas no significant reduction
was found in those that were either treated with C-
EGS324 or TK-EGS (Fig. 7). Thus, EGS324 is effective in
inhibiting HCMV infection and blocking viral growth.
Discussion
Compared to other nucleic acid-based gene interference
approaches, the EGS technology with the use of endoge-
nous human RNase P exhibits several unique and attrac-
tive features as a gene targeting tool. First, the mechanism
of the EGS technology for degradation of a specific
mRNA is different from other RNA- or DNA-based gene-
targeting approaches. It uses the endogenous RNase P,
which is one of the most ubiquitous, abundant, stable and
efficient enzymes in all type of cells. This essential
enzyme is highly expressed (5 × 104 copies per cell) and is
responsible for the processing of all tRNA precursors that
account for approximately 2% of total cellular RNA[24].
The action of RNase P with the EGS will result in irre-
versible cleavage of the target mRNA in a highly efficient
catalytic fashion. Second, the sequence specificity of the
EGS technology is governed by two different types of
interactions between the EGS and the target mRNA: the
base-pairing interactions in which the sequence of 12
nucleotides in the EGS hybridizes with the target mRNA,
and the interactions between the target mRNA and the
other part of the EGS sequence (equivalent to the T-stem
and T-loop, and variable regions of a tRNA) which are
required for folding of the RNase P-recognizable tertiary
structure. Thus, the EGS-based technology is highly spe-
cific and does not generate nonspecific "irrelevant cleav-
a g e "  t h a t  i s  o b s e r v e d  i n  R N a s e  H - m e d i a t e d  c l e a v a g e
induced by conventional antisense phosphorothioate
molecules [25].
Our study used exogenous administration of DNA-
based EGSs for antiviral applications and demonstrated
that RNase P-mediated targeting directed by DNA-based
EGS was highly effective in inhibiting HCMV gene
expression and viral growth in cultured cells. We showed
that these EGS molecules directed human RNase P to
cleave the UL49 mRNA sequence efficiently in vitro.
Moreover, we also showed that these EGSs were readily
delivered in cultured cells. A reduction of about 76~80%
Figure 4 Inhibition of HCMV UL49 expression in EGS-treated 
cells. HFFs (106) that were first treated with liposome complexes in the 
absence and presence of EGSs (100 nm) were either mock-infected or 
infected with HCMV at a moi of 1. At 72 hrs postinfection, total cellular 
RNAs were isolated, and then analyzed by quantative RT-PCR. The val-
ues shown are the means from triplicate experiments.
Figure 5 Inhibition directed by DNA-based EGS is dose-depen-
dent. Quantitative RT-PCR showed that when the concentration of 
EGS324 was 2.5 nM, the inhibition efficiency was 15%, and then 5 nM 
was 22%, 10 nM was 31%, 20 nM was 43%, 40 nM was 51%, 80 nM was 
75%, and 160 nM was 75.6%. Mock group was treated with a 50 bp ran-
dom DNA fragment.Zhang et al. Virology Journal 2010, 7:100
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in the UL49 expression was achieved with a functional
EGS, EGS324, whereas a reduction of less than 10% was
observed in cells that were treated with C-EGS324 or TK-
EGS. C-EGS324 bound to UL49 mRNA substrate in vitro
as well as EGS324 but contained nucleotide mutations
that disrupted RNase P recognition. These results sug-
gested that the overall observed inhibition with EGS324
was primarily due to targeted cleavage by RNase P as
opposed to the antisense effect or other nonspecific
effects of the EGSs. Moreover, the antiviral effect of the
EGS treatment (inhibition of viral growth) appeared to be
due to the reduction of the UL49 expression. Only the
expression of UL49 mRNA and protein was found to be
reduced in cells treated with EGS324. We found no signif-
icant change in the expression of IE2, UL44, pp28, and gB
(Table 1). The observed level of inhibition of UL49
expression was consistent with the extent of the reduc-
tion of viral growth.
HCMV is a member of the human herpesvirus family,
which includes seven other different viruses such as HSV
and Epstein-Barr virus. UL49 is well conserved and nec-
essary for the growth of this virus [16]. Therefore, UL49 is
considered as an ideal target for antiherpes therapy. To
develop EGSs as a conventional drug that can be used as
an exogenous agent for intracellular delivery in antiviral
therapy, EGSs containing modified oligonucleotides are
required to increase their stability in vivo [26,27]. It has
been recently reported that chemically synthesized RNA-
based EGSs with modified nucleotides can be adminis-
tered exogenously into human cells and inhibit cellular
gene expression [28]. Our study showed that exogenous
administration of DNA-based EGSs is highly efficient in
inhibiting gene expression and viral growth. Further
understanding of how the functional groups in the nucle-
otides of an EGS interact with human RNase P and the
mRNA substrate will lead to the construction of highly
active and stable EGSs with either different bases or mod-
ifications at these nucleotide positions. Moreover, engi-
neering different designs of EGSs [29] for increasing their
targeting activity, as well as developing new means for
improving their delivery, are needed to increase the effi-
cacy of the EGSs in vivo. These studies will facilitate the
Figure 6 In Western analyses (A&B), protein samples were sepa-
rated in two identical SDS-polyacrylamide gels and transferred 
electrically to two identical membranes. One membrane was al-
lowed to react with a anti-ul49 antibody (A), whereas the other was 
stained with the monoclonal antibody (Anti-actin) against human ac-
tin (B).
Table 1: Inhibiting rates of the mRNA and protein expression of different viral genes in cells.
Viral genes HFFs EGS324 C-EGS324 TK-EGS
UL49 mRNA 0% 76% ± 3% 8% 3%
IE2 mRNA 0% 0% 0% 0%
UL44 mRNA 0% 0% 0% 0%
UL49 protein 0% 80% ± 3% 6% 5%
I E 2  p r o t e i n 0 %0 %0 %1 %
G l y c o p r o t e i n  B 0 %2 %2 %1 %
pp28 protein 0% 1% 2% 1%
The values shown are the means from triplicate experiments, and values of standard deviation that were less than 5% are not shown.
Figure 7 Growth analysis of HCMV in human foreskin fibroblasts 
(HFFS) that were treated with liposome complexes in the absence 
of EGS, or in the presence of EGS324, C-EGS324 or TK-EGS. 1 × 105 
cells were first incubated with liposome complexes and then infected 
with HCMV at a moi of 1. Virus stocks were prepared from the infected 
cells at 1-day intervals through 7 days postinfection and viral titers 
were determined. The standard deviation is indicated by the error bars. 
These values are the means from triplicate experiments.Zhang et al. Virology Journal 2010, 7:100
http://www.virologyj.com/content/7/1/100
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development of the EGS-based technology for gene-tar-
geting applications in both basic research and clinical
therapy of HCMV infections.
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